ASH 2023 | Updated results of hyper-CVAD and blinatumomab +/- inotuzumab ozogamicin in newly-diagnosed B-ALL
Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the updated results of a Phase II study of hyper-CVAD chemotherapy (cyclophosphamide, vincristine, doxorubicin, and dexamethasone), with or without inotuzumab ozogamicin, and sequential blinatumomab in patients with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL). Survival outcomes in this study were very promising, and this therapeutic approach of shorter-duration chemotherapy with upfront immunotherapy will likely be useful in older patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
You know, the revolution in ALL that is happening today, is we’re improving the cure rate in adults and coming closer in pediatric [patients]. Historically, for patients up to the age of 60, the survival has been only around 50% in the long run. So, in this study, we said we’re going to shorten the chemotherapy and integrate immunotherapy upfront -so four hyper-CVAD, four blina -and then we added on top of that inotuzumab at a low dose (2...
You know, the revolution in ALL that is happening today, is we’re improving the cure rate in adults and coming closer in pediatric [patients]. Historically, for patients up to the age of 60, the survival has been only around 50% in the long run. So, in this study, we said we’re going to shorten the chemotherapy and integrate immunotherapy upfront -so four hyper-CVAD, four blina -and then we added on top of that inotuzumab at a low dose (2.4mg squared) to avoid complications. And we shortened the maintenance from 30 months to 12 course of POMP with one blina after every three POMP. We have a universal response rate, MRD-negativity by NGS is 80%, and our survival today at 3/4 years is 90%. Short chemotherapy, immunotherapy upfront and a survival of 90%. When you compare hyper-CVAD, blina, inotuzumab to the hyper-CVAD regular regimen, we have an improvement of survival from 60% to 85%, which is really great.
Read more...
Disclosures
Consultancy: Ascentage Pharma Group, Hikma Pharmaceuticals, Genentech, Pfizer, Amgen, Adaptive Biotech, Takeda, Novartis, Bristol-Myers Squibb, Abbvie
Honoraria: Ascentage Pharma Group, Hikma Pharmaceuticals, Genentech, Pfizer, Amgen, Adaptive Biotech, Takeda, Astex, Bristol-Myers Squibb, Abbvie
Research Funding: Ascentage Pharma Group, Hikma Pharmaceuticals, Genentech, Pfizer, Amgen, Adaptive Biotech, Takeda, Novartis, Astex, Bristol-Myers Squibb, Abbvie
